HRTX vs RCEL
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
HRTX presents a high-risk profile characterized by a stable but mediocre Piotroski F-Score of 4/9 and a complete lack of positive technical momentum (0/100). While the company maintains strong gross margins (72.64%) and a healthy current ratio (2.48), these are overshadowed by an extreme Debt/Equity ratio of 9.81 and a catastrophic 5-year price decline of 94.8%. There is a severe disconnect between the 'Strong Buy' analyst consensus with a $4.33 target and the actual market performance and fundamental leverage.
RCEL presents a high-risk profile characterized by a stable Piotroski F-Score (5/9) that masks severe underlying liquidity and solvency issues. The company exhibits negative shareholders' equity (Price/Book: -9.43) and a critical liquidity shortage with a current ratio of 0.57, indicating an inability to cover short-term obligations. Despite strong gross margins (82.13%) and bullish analyst targets, the fundamental trend is negative with shrinking revenue (-4.30%) and a consistent history of missing earnings estimates.
Compare Another Pair
Related Comparisons
HRTX vs RCEL: Head-to-Head Comparison
This page compares Heron Therapeutics, Inc. (HRTX) and AVITA Medical, Inc. (RCEL) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.